5 completed, 1 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow tizanidine: new trials by email Literature Review of tizanidine trials Research Report on tizanidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies Tizanidine, Vemurafenib - Malignant Melanoma, Neoplasms | Phase 1 | Completed | Hoffmann-La Roche | 18 | 2013-09-02 | 2017-03-20 |
| Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy Zanaflex Capsules - Spasticity Due to Cerebral Palsy | Phase 1 | Terminated | Acorda Therapeutics | 10 | 2011-05-01 | 2013-06-17 |
| Drug Discrimination in Methadone-Maintained Humans Study 3 2-4 of the drugs listed below - Drug Dependence | Phase 1 | Completed | University of Arkansas | 9 | 2010-02-01 | 2013-03-07 |
| Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity Tizanidine (sublingual or oral) - Muscle Spasticity | Phase 1 / Phase 2 | Completed | Teva GTC | 20 | 2006-12-01 | 2009-01-21 |
| Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions Tizanidine - Healthy | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 24 | 2001-09-01 | 2010-02-10 |
| Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions Tizanidine - Healthy | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 42 | 2001-09-01 | 2012-01-13 |
Melanoma (1) · Multiple Sclerosis (1) · Muscle Spasticity (1) · Neoplasms (1) · Opioid-Related Disorders (1) · Substance-Related Disorders (1)
Dr. Reddy's Laboratories Limited (2) · Acorda Therapeutics (1) · Hoffmann-La Roche (1) · Teva GTC (1) · University of Arkansas (1)
Canada (3) · United States (3) · Brazil (1) · Cyprus (1) · Israel (1) · South Korea (1)
Benoit Girard, M.D (2) · Alison Oliveto, Ph.D. (1) · Arnon Karni, MD (1) · Herbert Henney, PharmD (1)
R01DA010017 (1)